Lactose India Ltd — Important, 16-02-2026: Company Update

Lincoln Pharma reported strong Q3 FY26 financial results. Net profit increased 37.70% to ₹28.60 Cr, with revenue from operations reaching ₹166.32 Cr. EBITDA also rose 18.73% to ₹38.74 Cr. A credit rating on its bank facilities was reaffirmed, highlighting strong promoter experience and a healthy financial profile. The company targets ₹1,000 Cr revenue within three years, aiming for 15-18% annual growth by expanding into high-value product lines and new markets, especially in cardiac and dermatology segments. FIIs held 4.70%.